BAT1 (D6S81E, UAP56 ) lies in the central MHC between TNF and HLA-B, a region containing genes that affect susceptibility to immunopathologic disorders. BAT1 protein may be directly responsible for the genetic association, as antisense studies show it can down-regulate inflammatory cytokines. Here we investigate polymorphisms at positions -22 and -348 relative to the BAT1 transcription start site. DNA samples from healthy donors were used to confirm haplotypic associations with the type 1 diabetes-susceptible 8.1 ancestral haplotype (AH; HLA-A1,B8,BAT1-22*C,BAT1-348*C,DR3 ) and the diabetes-resistant 7.1 AH (HLA-A3,B7,BAT1-22*G,BAT1-348*T,DR15 ). Alleles carried at BAT1-22 and -348 were in linkage disequilibrium. Electrophoretic mobility shift assays using nuclear proteins from T-cells (Jurkat and HT2), monocytes (THP1, U937) and epithelial cells (HeLa and MDA468) demonstrated DNA : protein complexes binding oligonucleotides spanning positions -22 and -348 on the 7.1 AH only. Competition assays, supershifts and molecular weight determinations suggest the complexes include the transcription factors YY1 (at -348) and Oct1 (at -22). Promoter activity was demonstrated using 520 bp and 336 bp fragments cloned from immediately upstream of the transcription start site and carrying all combinations of -22 and -348 alleles, suggesting an unidentified nonpolymorphic sequence within 336 bp of the start site drives transcription. The 520 bp fragment of the BAT1 promoter cloned from the 8.1 AH was slightly less efficient than the equivalent from the 7.1 AH, whilst the reverse was observed with 336 bp fragments. This suggests BAT1 transcription on the 7.1 AH is modified by interactions involving DNA flanking positions -22 and -348.
INTRODUCTION
The human BAT1 gene (D6S81E, UAP56) is a member of the DEAD-box family of ATP-dependent RNA helicases (1) . It is located in the central major histocompatibility complex (MHC) on chromosome 6, in a region affecting several immunopathological disorders (2) (3) (4) . Fine mapping of the gene(s) affecting disease is limited by linkage disequilibrium within the MHC. We have defined a group of six genes (LTA, LTB, TNF, IKBL, AT6PG and BAT1) which is conserved through modern human evolution (5) and are evaluating each constituent gene as candidate for the observed genetic associations. Here we describe our investigation of BAT1.
Our studies suggest that BAT1 affects a process relevant in disease. Monocyte and T-cell lines infected with retroviral constructs containing BAT1 antisense sequence produced higher levels of the acute phase cytokines TNF, interleukin-1 (IL-1) and IL-6 than cells infected with the vector alone. These results suggested that BAT1 protein is a negative regulator of inflammation (6) . We also described 10 single nucleotide polymorphisms in the 1500 bp proximal promoter region of BAT1 in EBV-transformed B-cell lines homozygous for conserved MHC haplotypes (7) . The coding region was monomorphic, except for a synonymous substitution at position þ348.
As our aim is to identify polymorphisms that mediate susceptibility to type 1 diabetes, we use the 7.1 ancestral haplotype (AH; HLA-A3,B7,DR15), which is associated with dominant resistance, and the 8.1 AH (HLA-A1,B8,DR3), which confers susceptibility. We established that the first 520 bp of the BAT1 promoter allele 1 (7.1 AH) activates transcription more efficiently in Jurkat cells compared to allele 2 (8.1 AH haplotype). These alleles differ only at positions -22 and -348 in the 520 bp upstream of BAT1. Electrophoretic mobility shift assays (EMSA) demonstrated that both polymorphisms affect binding of nuclear proteins in Jurkat cells (7) . Here we show that both loci contribute to the difference in transcriptional activity between the alleles carried on the 7.1 AH or 8.1 AH, and identify transcription factors binding differentially to the two alleles in cells of different lineages.
RESULTS

Haplotypic associations between BAT-22 and -348 in healthy donors
DNA from 296 donors from the West Australian Bone Marrow registry was genotyped for alleles of BAT1-22 and BAT1-348. Alleles carried at BAT1-22 and -348 were in significant linkage disequilibrium, with no donors homozygous for BAT1-22*CC/-348*TT (Table 1) . Using a panel of workshop cell lines, we have shown previously that BAT1-22*C/-348*C is carried on the 8.1 AH and BAT1-22*G/-348*T is carried on the 7.1 AH. To confirm this association in a normal population, we examined the HLA-B and HLA-DR alleles carried by individuals who were homozygous for BAT1-22*C/BAT1-238*C or homozygous for BAT1-22*G/BAT1-348*T (Table 2) . Of the 32 individuals homozygous for BAT1-22*C/BAT1-348*C, 19 carried HLA-B8 and HLA-DR3 including seven individuals homozygous for these alleles. Of the remaining 13, none carried HLA-B7 or DR15. Thus BAT1-22G occurs on the 8.1 AH and not on the 7.1 AH. Similarly, of the 16 individuals homozygous for BAT1-22*G/BAT1-348*T, 10 also carried HLA-B7 and HLA-DR15, including one individual who was homozygous. The only trace of an 8.1 AH was one donor carrying HLA-B8. Hence, BAT1-22*G/BAT1-348*T occurs on the 7.1 AH and not on the 8.1 AH.
Nuclear factors bind to sequences flanking BAT1-22*G and -348*T in multiple cell lines Nuclear extracts from cells of six lineages were incubated with 32 P-labelled probes spanning BAT1-22 and -348 (Fig. 1) . Bands A and D were generated by the BAT1-22 probe using all cell lineages [T-cells (Jurkat and HT2), monocytes (THP1, U937) and epithelial cells (HeLa and MDA468)], as previously in Jurkat cells (7) . Band A reflects specific binding to BAT1-22*G, since a 100-fold molar excess of unlabelled oligonucleotide inhibited binding of the labeled probe. Unlabelled probe carrying the alternative allele did not inhibit this band (data not shown). Band D was not allele-specific, so further analyses focused on Band A. Two intermediate bands (b and c) displayed variable intensity and were not uniformly inhibited by excess unlabelled probe in replicate studies (data not shown), so they were not investigated further.
Probes spanning BAT1-348 generated several bands (e,f,G,h). Band G was observed with extracts from all cell lines reacted with the BAT1-348*T probe, but not with BAT1-348*C. Incubation with excess unlabelled homologous oligonucleotide substantially reduced the intensity of Band G. Bands e, f and h were weak, variable and not reproducibly reduced by competition with excess unlabelled homologous oligonucleotide.
Nuclear factors binding to BAT1-22*G (Band A) and BAT1-348*T (Band G) can be inhibited by transcription factor consensus oligonucleotides Jurkat nuclear extracts were probed using oligonucleotides containing the consensus-binding motif sequence for a series of transcription factors as unlabelled competitors (Fig. 2) . GATA, NFAT and Oct1 consensus oligonucleotides inhibited Band A (seen with the BAT1-22*G probe). Incomplete competition occurred with the consensus dEF1 and CREB oligonucleotides. Band G (seen with the BAT1-348*T probe) was inhibited by consensus NFAT and YY1 oligonucleotides.
Molecular mass of proteins binding selectively to BAT1-22*G and -348*T Jurkat nuclear extracts were incubated with the labelled oligonucleotides and then UV irradiated to cross-link proteins to the DNA. The samples were then denatured and separated by electrophoresis on 10% SDS-PAGE gels. Competition with excess unlabelled oligonucleotides was used to assess specificity.
The BAT1-22*G probe produced strong bands with approximate molecular weights of 66-70 and 95-100 kDa. These were not seen with the -22*C probe and were inhibited by excess unlabeled oligonucleotides (Fig. 3) , so both may reflect components of Band A on the original EMSA (Fig. 1 ). Other bands were weaker, not allele-specific and/or not inhibited by unlabelled oligonucleotides. The BAT1-348*T probe also generated multiple bands (Fig. 3 ), but only the 68 kDa band was allele-specific and inhibited by unlabelled oligonucleotide. We suggest this protein represents Band G on the original EMSA ( Fig. 1 ).
Oct1 and YY1 factors form sequence-specific complexes with the polymorphic promoter elements of the BAT1 gene Using Jurkat cell nuclear extract and labeled BAT1-22*G probe, anti-Oct1 antibody substantially inhibited Band A and produced a low mobility complex (Fig. 4A , lane 4). Anti-Oct2 antibody had no effect (lane 5). Labeled consensus Oct1 oligonucleotide generated a complex equivalent to Band A (lane 6), which was inhibited by unlabeled BAT1-22*G oligonucleotide but not by BAT1-348*T. This band could be supershifted with anti-Oct1, suggesting Oct1 is an integral part of Band A-binding to the DNA if the G allele is present. Its molecular weight is consistent with the larger specific band demonstrated by UV-crosslinking (95-100 kDa; Fig. 3 ). When the consensus YY1 oligonucleotide was used as a probe, the major complex was smaller than Band A ( The complex generated with labelled YY1 consensus oligonucleotide resembled Band G generated with BAT1-348*T, and was partially blocked by competition with unlabelled BAT1-348*T oligonucleotide but not BAT1-22*G ( NFAT consensus sequence blocked Bands A and G (Fig. 2) . When used as a probe this produced a band which corresponded to Band G, suggesting binding around -348*T. However the NFAT band was only marginally inhibited by excess BAT1-348*T and not affected by BAT1-22*G (Fig. 4D) , so the inhibition of Band A is considered non-specific. An extensive series of antibodies was tested but did not cause a supershift using -348*T (data not shown) or NFAT consensus sequence (Fig. 4D) as a probe, so we were unable to confirm that NFAT is a component of Band G. Moreover our UVcrosslinking study (Fig. 3) suggests a single protein binds to -348*T, which appears to be YY1.
When consensus sequences for the other transcription factors able to inhibit binding to the BAT1 promoter (GATA, dEF1 and CREB; Fig. 2 ) were used as probes, the bands did not correspond with those obtained with the BAT1-22*G probe (Band A) or BAT1-348*T probe (Band G) (Fig. 4E ).
BAT1-22 and -348 affect transcription of reporter constructs
Four luciferase reporter constructs containing 520 bp of DNA upstream of the transcription start site were generated to assess all combinations of alleles at -22 and -348 (Table 1) . Consistent with our previous studies (7), the relative luciferase activity of promoter with alleles (-22*C/-348*C) (i.e. from the 8.1 AH) was lower than that of a promoter carrying (-22*G/-348*T). However, all promoter fragments induced luciferase activity, suggesting non-polymorphic sequences within the promoter drive basal transcription. Moreover, luciferase activities induced by promoters carrying (-22*C/-348*T) or (-22*G/-348*C) were similar to that of promoters carrying (-22*G/-348*T) ( Table 3 ). The simplest explanation for this is that binding of nuclear proteins to either site in the 7.1 AH promoter is sufficient to increase transcription above that seen with the 8.1 AH. Lower reporter gene expression for the 520 bp BAT1 promoter fragment from the 8.1 AH was confirmed over an extensive time course by flow cytometry using HeLa cells transfected with fluorescent reporter constructs (Fig. 5 , Exp. 1). To further address the contributions of the -22 and -348 sequences, 520 bp fragments of the 8.1 AH and 7.1 AH were compared with 336 bp fragments lacking BAT1-348. The 336 bp promoter from the 8.1 AH showed higher reporter activity than that from the 7.1 AH (Fig. 5, Exp. 2B ). This finding was not expected as a follow-on from the data in Table  3 and may reflect the binding of unidentified proteins to nonpolymorphic sequences affected by the truncation. Cell lineage may affect interactions between the -22 and -348 sequences, though the EMSA data ( Fig. 1) and transfected 520 bp promoter fragments (Table 3 and Fig. 5 , Exp. 1) would not support this.
BAT1 mRNA is expressed in the cell types used to analyse transcription BAT1 mRNA expression was assessed using real-time RT-PCR in Jurkat and HeLa cells and PBMC from single adult male donors homozygous for the 7.1 AH and 8.1 AH. Levels of expression were 146, 154, 103 and 128, respectively (mean of duplicate determinations expressed relative to b-actin mRNA Â 10 À3 ). Thus BAT1 is widely expressed, but the in vivo effects of promoter genotype require further analysis.
DISCUSSION
This study demonstrates that combinations of alleles carried at -22 and -348 relative to the transcription start site of the BAT1 gene are in linkage disequilibrium (Table 1) and distinguish the 7.1 AH and 8.1 AH in a normal population (Table 2) , although they are not unique to either AH. The alleles have moderate effects on transcription (Table 3 and Fig. 5 ). Since promoters from both alleles drive transcription efficiently, we conclude that the polymorphisms affect regulatory regions rather than sequences essential for transcription initiation. This conclusion is consistent with the high species conservation of BAT1 and the absence of coding polymorphisms, which suggest it is essential to life (1, 8, 9) .
Binding of nuclear proteins to DNA flanking -22 and -348 was restricted to the 7.1 AH promoter, independent of cell lineage (Fig. 1) . The proteins are tentatively identified as YY1 (binding directly at -348 and indirectly at -22) and Oct1 (binding directly at -22), based on competition with oligonucleotides carrying the consensus binding sequences, supershift assays and molecular weight determinations from protein : DNA UV-crosslinking (Figs 2-4) . As the YY1 consensus oligonucleotide did not inhibit Band A, the supershift detected with YY1 antibody may be an artefact or YY1 (or an antigenically-related protein of similar molecular weight) may bind indirectly around -22. The polymorphic site at position -22 lies within the core consensus sequence for Oct1 (GCAAAT), but both alleles are discordant (GCACAT and GCAGAT). BAT1-348*T carries the core binding sequence for YY1 (CCAT ), whilst the equivalent sequence for BAT1-348*G is CCAC. This change would be expected to affect binding of YY1. Further analyses of YY1 binding using transcription factor databases produced widely divergent outcomes depending on the length of sequence and the database selected. For example, whilst the YY1 consensus sequence used here matched that used by Mordvinov et al. (10) , multiple different consensus sequences are described by Zabel et al. (11) . It is notable that several studies show interactions with YY1 at several sites in the same promoter (11, 12) , consistent with our finding that alleles at -22 and -348 affect BAT1 expression via YY1 (Table 3 and Fig. 5 ).
YY1 and Oct1 have complex roles in regulation of gene expression. YY1 (Yin Yang1) is best known for its ability to suppress or activate transcription depending on other features of the cell and/or promoter. For example; YY1 mediates transcriptional repression of the gene encoding interferon-g by inhibiting AP1 binding in Jurkat human T-cells (12) , and can function as a transcriptional activator for interferon-g by interacting with NFAT in primary murine splenocytes (13) . Interactions between Oct1 and YY1 have been implicated in the down regulation of IL-5 in T-cells (10) . The possibility that YY1 and NFAT may interact at position -348*T to produce Band G (Figs 2 and 4D ) requires further study.
In conclusion, our programme of research has defined a series of criteria required to evaluate polymorphisms that may be responsible for associations between conserved MHC haplotypes and complex disease traits (2). Through recombinant mapping we established that BAT1 lies in a region of the MHC which contains genes that influence the development or severity of several immunopathological conditions. We then showed BAT1 had a function relevant to disease, specifically as a negative regulator of inflammatory cytokines (6) . Finally, we showed that transcription driven by the BAT1 promoter 
MATERIALS AND METHODS
Genotyping
Healthy donors from the Western Australian Bone Marrow Registry were used to establish haplotypic associations. HLA typing and DNA extractions were performed as described previously (3) . Alleles carried at -22 and -348 were determined by Amplifluor methodology at the Centre Nationale de Genotypage (Paris, France) (R.J.N. Allcock et al., submitted for publication).
Electrophoretic mobility shift assays (EMSA)
EMSA were performed using single-stranded oligonucleotides (Table 4 ; GeneWorks, South Australia and Santa Cruz, USA), annealed and gel purified according to standard protocols (7). T4 polynucleotide kinase was used to label oligonucleotides with [g-32 P]-ATP. Cell extracts were prepared as described by Schreiber et al. (14) with minor modifications: Protease inhibitor cocktail (Boehringer Mannheim, Germany), 1 mM Na 3 VO 4 (Sigma, USA) and 0.5 mM DTT (Sigma, USA) were added to reaction buffers prior to lysis. Protein concentrations were determined using a DC Protein Assay (Bio-Rad, USA).
Standard EMSA binding reactions contained 3 mg nuclear extract, 1 mg poly(dI-dC) (Pharmacia, USA), 12 mM HEPES (pH 7.9), 60 mM KCl, 0.1 mM EDTA, 12% glycerol, 1 mM DTT, 1 mM Na 3 VO 4 , Protease Inhibitor Cocktail and 25 fmol 32 P-labelled double-stranded oligonucleotide probe. Nuclear extracts were incubated in the reaction buffer, followed by 32 P-labelled DNA probe (each 30 min on ice). DNA-protein complexes were resolved by polyacrylamide gel electrophoresis (PAGE). X-ray films were exposed with intensifying screens at À70 C. Competition assays utilized 100-fold molar excess of unlabeled double-stranded oligonucleotides, added to the binding reaction 30 min before the labelled oligonucleotide. Super-shift assays utilized 1-2 ml antibody (100 mg/ml; Santa Cruz, USA), added to the binding reaction 60 min before the labelled DNA probe.
To determine the molecular masses of nuclear factors binding to the BAT1 promoter, labelled oligonucleotides and nuclear extracts were mixed and UV-irradiated (Strata-linker; USA) at 999 mV for 8 min. Standard SDS-PAGE loading dye was added for denaturation at 95 C for 5 min. UV-crosslinked DNA : protein complexes were separated on 10% SDS-PAGE gels, alongside 14 C-Rainbow TM protein molecular weight markers (Amersham, UK).
Reporter constructs
Inserts carrying -22*G with -348*T (7.1 AH), -22*C with -348*C (8.1 AH) and -22*G with -348*C (18.1 AH; HLA-B18,DR15) were generated by PCR amplification of genomic DNA from homozygous EBV-transformed B-cell lines carrying these haplotypes (7) . Amplicons were purified and directionally ligated into the multiple cloning site of a promoter-less luciferase-encoding plasmid (pGL3-enhancer, Promega, USA). Inserts carrying -22*C with -348*T were generated by BglII/BglI digestion and re-ligation of DNA fragments derived C for 10 min, followed by 18 cycles of 95 C for 30 s, 52 C for 1 min and 68 C for 15 min, and extension at 68 C for 15 min. Following amplification, the methylated parental templates were removed by DpnI (20 U, New England Biolabs, USA) digestion at 37 C for 2 h. The resulting DNA (2.5 ml) was introduced into Escherichia coli by standard heat-shock transformation. To generate a Figure 4 . Identity of nuclear binding proteins was established using 32 P-labeled BAT1-22*G, BAT1-348*T or specific transcription factor consensus oligonucleotides as probes, with Jurkat nuclear extracts. Binding profiles of Oct1 and BAT1-22 oligonucleotides were similar (A), as were profiles of YY1 and BAT1-348 oligonucleotides (C). YY1 and BAT1-22 probes produced distinct bands, but polyclonal anti-YY1 blocked Band A, so YY1 may form part of a large complex at this site (B). Bands produced by NFAT oligonucleotide were marginally inhibited by unlabelled BAT1-348, but not by any available antibody (see text; D). Other consensus oligonucleotides did not produce bands similar to BAT1-22 or -348 (E). Table 3 . Dual-Luciferase reporter activity generated by a 520 bp promoter fragment encompassing BAT1-22*C and -348*C is low in Jurkat T-cells plasmid lacking BAT1-348, the -520 to -336 region of the BAT1 promoter was removed by digestion and re-ligation in the presence of SacI.
Culture and transfection of mammalian cell lines
Jurkat, THP1, U937, HeLa and MDA468 cells from the American Type Culture Collection (USA) were cultured in RMPI-1640 medium with 10% foetal calf serum. Peripheral blood mononuclear cells (PBMC) were isolated using FicollHypaque density gradient separation. BAT1 reporter plasmids were co-transfected with a control reporter marker into Jurkat or Hela cells using Fugene (Boehringer Mannheim, Germany) or Lipofectamine (Invitrogen, USA), according to manufacturers' instructions For luciferase reporter vectors, cells were harvested and resuspended in 100 ml passive lysis buffer. Cell lysates were cleared by centrifugation and 40 ml aliquots assayed using the Dual Luciferase Assay Kit (Promega, USA). Light emission (wavelength 300-650 nm) was measured in a Victor 1420 multilabel reader for 10 s (Wallac, USA). Values were normalized for transfection efficiency by dividing test reporter activity by values obtained for Renilla luciferase activity. The promoter less control vector (pGL3-enhancer; Promega, USA) and a vector containing an SV40 promoter (pGL3-control; Promega, USA) were included as controls.
For the vectors containing EGFP, HeLa cells (50-70% of confluency in 75 cm 2 flask) were co-transfected with 5 mg DNA using Lipofectamine 2000 (Invitrogen, USA). As an internal control of transfection efficiency, 1.5 mg BTR1N4 vector (D. Voon et al., manuscript in preparation) expressing HcRed was co-transfected with 3.5 mg of each BAT1 promoter construct. Six hours after transfection, cells were split into 6 cm petri dishes, one per time point. Cells were harvested at the required times by trypsinization. Expression of EGFP and HcRed was measured on a flow cytometer (Coulter, USA) and analysed using FlowJo software (Tree Star, USA). Quantification of mRNA by real-time PCR RNA was extracted using the RNeasy total RNA kit for cDNA synthesis using Omniscript (Qiagen, USA). PCR was performed on a LightCycler TM (Roche) in 20 ml volumes containing 1.25 mM dNTP, 20 pmol each primer, 0.25 mg/ml bovine serum albumin and 1.5 units Platinum Taq DNA polymerase. Primer sequences were 5 0 -GATGACCCAGATCATGTTTGA-3 0 and 5 0 -GACTCCATGCCCAGGAAGGAA-3 0 for b-actin and 5 0 -AG AGGCTTTCTCGGTATCA-3 0 and 5 0 -CATCAGGCAGCTCAC TAA-3 0 for BAT1. The PCR protocol comprised 95 C for 5 min, and 35 cycles of 95 C for 2 s, 62-64 C for 10 s and 72 C for 20 s. Product formation was monitored using SYBR Green fluorochrome (Sigma, USA), generation of a single product was confirmed from the melting curve and quantitation utilized standard curves generated from serial 10-fold dilutions of purified PCR products. Ratios of BAT1 to b-actin amplicons were multiplied by 1000 to yield whole numbers.
